Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences

Dow Jones

05/09

By Kelly Cloonan

Kestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday.

First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours.

Inhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 08, 2026 18:40 ET (22:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2634498342"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634498342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634498342?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634498342","market":"hk","top_or_hot":-1,"title":"Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KG\">Kestrel</a> Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n</p>\n<p>\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-09 06:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KG\">Kestrel</a> Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n</p>\n<p>\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634498342","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634498342","pubTimestamp":1778280000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday.First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours.Inhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KG":"Kestrel","INBX":"Inhibrx Biosciences","BK4019":"再保险"},"translate_title":"值得关注的股票：Kestrel Group、First Tracks Biotherapeutics、Inhibrx Biosciences","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KG":1.5,"INBX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\nKestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n\n\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n\n\nInhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 18:40 ET (22:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}